ID   CLOCK_HUMAN             Reviewed;         846 AA.
AC   O15516; A0AV01; A2I2N9; O14516; Q9UIT8;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   10-MAY-2017, entry version 178.
DE   RecName: Full=Circadian locomoter output cycles protein kaput;
DE            Short=hCLOCK;
DE            EC=2.3.1.48;
DE   AltName: Full=Class E basic helix-loop-helix protein 8;
DE            Short=bHLHe8;
GN   Name=CLOCK; Synonyms=BHLHE8, KIAA0334;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND TISSUE SPECIFICITY.
RX   PubMed=10198158; DOI=10.1006/geno.1998.5675;
RA   Steeves T.D.L., King D.P., Zhao Y., Sangoram A.M., Du F.,
RA   Bowcock A.M., Moore R.Y., Takahashi J.S.;
RT   "Molecular cloning and characterization of the human CLOCK gene:
RT   expression in the suprachiasmatic nuclei.";
RL   Genomics 57:189-200(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (SEP-2006) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=9205841; DOI=10.1093/dnares/4.2.141;
RA   Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. VII.
RT   The complete sequences of 100 new cDNA clones from brain which can
RT   code for large proteins in vitro.";
RL   DNA Res. 4:141-150(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-349.
RC   TISSUE=Brain;
RA   Ikeda M., Takehara N., Ebisawa T., Yamauchi T., Nomura M.;
RT   "Molecular cloning of human Clock cDNA 5'-end.";
RL   Submitted (AUG-1997) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   DNA-BINDING, AND ENZYME REGULATION.
RX   PubMed=11441146; DOI=10.1126/science.1060698;
RA   Rutter J., Reick M., Wu L.C., McKnight S.L.;
RT   "Regulation of clock and NPAS2 DNA binding by the redox state of NAD
RT   cofactors.";
RL   Science 293:510-514(2001).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH KAT2B; CREBBP AND
RP   EP300.
RX   PubMed=14645221; DOI=10.1074/jbc.M311973200;
RA   Curtis A.M., Seo S.B., Westgate E.J., Rudic R.D., Smyth E.M.,
RA   Chakravarti D., FitzGerald G.A., McNamara P.;
RT   "Histone acetyltransferase-dependent chromatin remodeling and the
RT   vascular clock.";
RL   J. Biol. Chem. 279:7091-7097(2004).
RN   [9]
RP   MUTAGENESIS OF GLU-116; GLY-332; HIS-360; GLU-367; VAL-601 AND
RP   PRO-840.
RX   PubMed=16474406; DOI=10.1038/ng1745;
RA   Sato T.K., Yamada R.G., Ukai H., Baggs J.E., Miraglia L.J.,
RA   Kobayashi T.J., Welsh D.K., Kay S.A., Ueda H.R., Hogenesch J.B.;
RT   "Feedback repression is required for mammalian circadian clock
RT   function.";
RL   Nat. Genet. 38:312-319(2006).
RN   [10]
RP   FUNCTION.
RX   PubMed=18587630; DOI=10.1007/s11010-008-9846-x;
RA   Li R., Yue J., Zhang Y., Zhou L., Hao W., Yuan J., Qiang B.,
RA   Ding J.M., Peng X., Cao J.M.;
RT   "CLOCK/BMAL1 regulates human nocturnin transcription through binding
RT   to the E-box of nocturnin promoter.";
RL   Mol. Cell. Biochem. 317:169-177(2008).
RN   [11]
RP   INTERACTION WITH ID2.
RX   PubMed=20861012; DOI=10.1074/jbc.M110.175182;
RA   Ward S.M., Fernando S.J., Hou T.Y., Duffield G.E.;
RT   "The transcriptional repressor ID2 can interact with the canonical
RT   clock components CLOCK and BMAL1 and mediate inhibitory effects on
RT   mPer1 expression.";
RL   J. Biol. Chem. 285:38987-39000(2010).
RN   [12]
RP   INTERACTION WITH ARNTL; CRY1 AND PER2.
RX   PubMed=21613214; DOI=10.1074/jbc.M111.254680;
RA   Ye R., Selby C.P., Ozturk N., Annayev Y., Sancar A.;
RT   "Biochemical analysis of the canonical model for the mammalian
RT   circadian clock.";
RL   J. Biol. Chem. 286:25891-25902(2011).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH NR3C1.
RX   PubMed=21980503; DOI=10.1371/journal.pone.0025612;
RA   Charmandari E., Chrousos G.P., Lambrou G.I., Pavlaki A., Koide H.,
RA   Ng S.S., Kino T.;
RT   "Peripheral CLOCK regulates target-tissue glucocorticoid receptor
RT   transcriptional activity in a circadian fashion in man.";
RL   PLoS ONE 6:E25612-E25612(2011).
RN   [14]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=21659603; DOI=10.1126/science.1203430;
RA   Cotta-Ramusino C., McDonald E.R. III, Hurov K., Sowa M.E.,
RA   Harper J.W., Elledge S.J.;
RT   "A DNA damage response screen identifies RHINO, a 9-1-1 and TopBP1
RT   interacting protein required for ATR signaling.";
RL   Science 332:1313-1317(2011).
RN   [15]
RP   INTERACTION WITH KDM5A.
RX   PubMed=21960634; DOI=10.1126/science.1206022;
RA   DiTacchio L., Le H.D., Vollmers C., Hatori M., Witcher M., Secombe J.,
RA   Panda S.;
RT   "Histone lysine demethylase JARID1a activates CLOCK-BMAL1 and
RT   influences the circadian clock.";
RL   Science 333:1881-1885(2011).
RN   [16]
RP   FUNCTION.
RX   PubMed=22284746; DOI=10.1111/j.1538-7836.2012.04643.x;
RA   Tracey C.J., Pan X., Catterson J.H., Harmar A.J., Hussain M.M.,
RA   Hartley P.S.;
RT   "Diurnal expression of the thrombopoietin gene is regulated by
RT   CLOCK.";
RL   J. Thromb. Haemost. 10:662-669(2012).
RN   [17]
RP   REVIEW.
RX   PubMed=23576606; DOI=10.1152/ajpregu.00066.2013;
RA   Richards J., Gumz M.L.;
RT   "Mechanism of the circadian clock in physiology.";
RL   Am. J. Physiol. 304:R1053-R1064(2013).
RN   [18]
RP   PHOSPHORYLATION AT THR-451 AND THR-461, MUTAGENESIS OF THR-451 AND
RP   THR-461, AND INTERACTION WITH THE COMPLEX P35/CDK5.
RX   PubMed=24235147; DOI=10.1074/jbc.M113.494856;
RA   Kwak Y., Jeong J., Lee S., Park Y.U., Lee S.A., Han D.H., Kim J.H.,
RA   Ohshima T., Mikoshiba K., Suh Y.H., Cho S., Park S.K.;
RT   "Cyclin-dependent kinase 5 (Cdk5) regulates the function of CLOCK
RT   protein by direct phosphorylation.";
RL   J. Biol. Chem. 288:36878-36889(2013).
RN   [19]
RP   FUNCTION.
RX   PubMed=23785138; DOI=10.1523/JNEUROSCI.2757-12.2013;
RA   Baeza-Raja B., Eckel-Mahan K., Zhang L., Vagena E., Tsigelny I.F.,
RA   Sassone-Corsi P., Ptacek L.J., Akassoglou K.;
RT   "p75 neurotrophin receptor is a clock gene that regulates oscillatory
RT   components of circadian and metabolic networks.";
RL   J. Neurosci. 33:10221-10234(2013).
RN   [20]
RP   SUMOYLATION, SUBCELLULAR LOCATION, AND INTERACTION WITH ESR1.
RX   PubMed=23160374; DOI=10.1038/onc.2012.518;
RA   Li S., Wang M., Ao X., Chang A.K., Yang C., Zhao F., Bi H., Liu Y.,
RA   Xiao L., Wu H.;
RT   "CLOCK is a substrate of SUMO and sumoylation of CLOCK upregulates the
RT   transcriptional activity of estrogen receptor-alpha.";
RL   Oncogene 32:4883-4891(2013).
RN   [21]
RP   REVIEW.
RX   PubMed=23303907; DOI=10.1152/physrev.00016.2012;
RA   Eckel-Mahan K., Sassone-Corsi P.;
RT   "Metabolism and the circadian clock converge.";
RL   Physiol. Rev. 93:107-135(2013).
RN   [22]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=24005054; DOI=10.1038/jid.2013.366;
RA   Al-Nuaimi Y., Hardman J.A., Biro T., Haslam I.S., Philpott M.P.,
RA   Toth B.I., Farjo N., Farjo B., Baier G., Watson R.E., Grimaldi B.,
RA   Kloepper J.E., Paus R.;
RT   "A meeting of two chronobiological systems: circadian proteins Period1
RT   and BMAL1 modulate the human hair cycle clock.";
RL   J. Invest. Dermatol. 134:610-619(2014).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [24]
RP   REVIEW.
RX   PubMed=23916625; DOI=10.1016/j.tcb.2013.07.002;
RA   Partch C.L., Green C.B., Takahashi J.S.;
RT   "Molecular architecture of the mammalian circadian clock.";
RL   Trends Cell Biol. 24:90-99(2014).
RN   [25]
RP   ASSOCIATION WITH PASD1.
RX   PubMed=25936801; DOI=10.1016/j.molcel.2015.03.031;
RA   Michael A.K., Harvey S.L., Sammons P.J., Anderson A.P., Kopalle H.M.,
RA   Banham A.H., Partch C.L.;
RT   "Cancer/testis antigen PASD1 silences the circadian clock.";
RL   Mol. Cell 58:743-754(2015).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 29-89 IN COMPLEX WITH ARNTL
RP   AND DNA, FUNCTION, ENZYME REGULATION, SUBUNIT, AND MUTAGENESIS OF
RP   SER-38; SER-42; PHE-50 AND HIS-84.
RX   PubMed=23229515; DOI=10.1038/cr.2012.170;
RA   Wang Z., Wu Y., Li L., Su X.D.;
RT   "Intermolecular recognition revealed by the complex structure of human
RT   CLOCK-BMAL1 basic helix-loop-helix domains with E-box DNA.";
RL   Cell Res. 23:213-224(2013).
CC   -!- FUNCTION: Transcriptional activator which forms a core component
CC       of the circadian clock. The circadian clock, an internal time-
CC       keeping system, regulates various physiological processes through
CC       the generation of approximately 24 hour circadian rhythms in gene
CC       expression, which are translated into rhythms in metabolism and
CC       behavior. It is derived from the Latin roots 'circa' (about) and
CC       'diem' (day) and acts as an important regulator of a wide array of
CC       physiological functions including metabolism, sleep, body
CC       temperature, blood pressure, endocrine, immune, cardiovascular,
CC       and renal function. Consists of two major components: the central
CC       clock, residing in the suprachiasmatic nucleus (SCN) of the brain,
CC       and the peripheral clocks that are present in nearly every tissue
CC       and organ system. Both the central and peripheral clocks can be
CC       reset by environmental cues, also known as Zeitgebers (German for
CC       'timegivers'). The predominant Zeitgeber for the central clock is
CC       light, which is sensed by retina and signals directly to the SCN.
CC       The central clock entrains the peripheral clocks through neuronal
CC       and hormonal signals, body temperature and feeding-related cues,
CC       aligning all clocks with the external light/dark cycle. Circadian
CC       rhythms allow an organism to achieve temporal homeostasis with its
CC       environment at the molecular level by regulating gene expression
CC       to create a peak of protein expression once every 24 hours to
CC       control when a particular physiological process is most active
CC       with respect to the solar day. Transcription and translation of
CC       core clock components (CLOCK, NPAS2, ARNTL/BMAL1, ARNTL2/BMAL2,
CC       PER1, PER2, PER3, CRY1 and CRY2) plays a critical role in rhythm
CC       generation, whereas delays imposed by post-translational
CC       modifications (PTMs) are important for determining the period
CC       (tau) of the rhythms (tau refers to the period of a rhythm and is
CC       the length, in time, of one complete cycle). A diurnal rhythm is
CC       synchronized with the day/night cycle, while the ultradian and
CC       infradian rhythms have a period shorter and longer than 24 hours,
CC       respectively. Disruptions in the circadian rhythms contribute to
CC       the pathology of cardiovascular diseases, cancer, metabolic
CC       syndromes and aging. A transcription/translation feedback loop
CC       (TTFL) forms the core of the molecular circadian clock mechanism.
CC       Transcription factors, CLOCK or NPAS2 and ARNTL/BMAL1 or
CC       ARNTL2/BMAL2, form the positive limb of the feedback loop, act in
CC       the form of a heterodimer and activate the transcription of core
CC       clock genes and clock-controlled genes (involved in key metabolic
CC       processes), harboring E-box elements (5'-CACGTG-3') within their
CC       promoters. The core clock genes: PER1/2/3 and CRY1/2 which are
CC       transcriptional repressors form the negative limb of the feedback
CC       loop and interact with the CLOCK|NPAS2-ARNTL/BMAL1|ARNTL2/BMAL2
CC       heterodimer inhibiting its activity and thereby negatively
CC       regulating their own expression. This heterodimer also activates
CC       nuclear receptors NR1D1/2 and RORA/B/G, which form a second
CC       feedback loop and which activate and repress ARNTL/BMAL1
CC       transcription, respectively. CLOCK has an intrinsic
CC       acetyltransferase activity, which enables circadian chromatin
CC       remodeling by acetylating histones and nonhistone proteins,
CC       including its own partner ARNTL/BMAL1. Regulates the circadian
CC       expression of ICAM1, VCAM1, CCL2, THPO and MPL and also acts as an
CC       enhancer of the transactivation potential of NF-kappaB. Plays an
CC       important role in the homeostatic regulation of sleep. The CLOCK-
CC       ARNTL/BMAL1 heterodimer regulates the circadian expression of
CC       SERPINE1/PAI1, VWF, B3, CCRN4L/NOC, NAMPT, DBP, MYOD1, PPARGC1A,
CC       PPARGC1B, SIRT1, GYS2, F7, NGFR, GNRHR, BHLHE40/DEC1, ATF4, MTA1,
CC       KLF10 and also genes implicated in glucose and lipid metabolism.
CC       Represses glucocorticoid receptor NR3C1/GR-induced transcriptional
CC       activity by reducing the association of NR3C1/GR to glucocorticoid
CC       response elements (GREs) via the acetylation of multiple lysine
CC       residues located in its hinge region. Promotes rhythmic chromatin
CC       opening, regulating the DNA accessibility of other transcription
CC       factors. The CLOCK-ARNTL2/BMAL2 heterodimer activates the
CC       transcription of SERPINE1/PAI1 and BHLHE40/DEC1. The preferred
CC       binding motif for the CLOCK-ARNTL/BMAL1 heterodimer is 5'-CACGTGA-
CC       3', which contains a flanking Ala residue in addition to the
CC       canonical 6-nucleotide E-box sequence (PubMed:23229515). CLOCK
CC       specifically binds to the half-site 5'-CAC-3', while ARNTL binds
CC       to the half-site 5'-GTGA-3' (PubMed:23229515). The CLOCK-
CC       ARNTL/BMAL1 heterodimer also recognizes the non-canonical E-box
CC       motifs 5'-AACGTGA-3' and 5'-CATGTGA-3' (PubMed:23229515).
CC       {ECO:0000269|PubMed:14645221, ECO:0000269|PubMed:18587630,
CC       ECO:0000269|PubMed:21659603, ECO:0000269|PubMed:21980503,
CC       ECO:0000269|PubMed:22284746, ECO:0000269|PubMed:23229515,
CC       ECO:0000269|PubMed:23785138, ECO:0000269|PubMed:24005054}.
CC   -!- CATALYTIC ACTIVITY: Acetyl-CoA + [protein]-L-lysine = CoA +
CC       [protein]-N(6)-acetyl-L-lysine.
CC   -!- ENZYME REGULATION: There is conflicting data about the effect of
CC       NAD cofactors on activity. PubMed:11441146 suggests that the redox
CC       state of the cell can modulate the transcriptional activity of the
CC       CLOCK-ARNTL/BMAL1 heterodimer; NADH and NADPH enhance the DNA-
CC       binding activity of the heterodimer. PubMed:23229515 reports that
CC       NADH and NADPH have no significant effect on DNA-binding activity
CC       of the CLOCK-ARNTL/BMAL1 heterodimer.
CC       {ECO:0000269|PubMed:11441146, ECO:0000269|PubMed:23229515}.
CC   -!- SUBUNIT: Component of the circadian clock oscillator which
CC       includes the CRY proteins, CLOCK or NPAS2, ARNTL/BMAL1 or
CC       ARNTL2/BMAL2, CSNK1D and/or CSNK1E, TIMELESS and the PER proteins
CC       (By similarity). Interacts with KMT2A in a circadian manner (By
CC       similarity). Forms a heterodimer with ARNTL/BMAL1
CC       (PubMed:21613214, PubMed:23229515). The CLOCK-ARNTL/BMAL1
CC       heterodimer is required for E-box-dependent transactivation, for
CC       CLOCK nuclear translocation and degradation, and for
CC       phosphorylation of both CLOCK and ARNTL/BMAL1 (By similarity).
CC       Interacts with NR3C1 in a ligand-dependent fashion
CC       (PubMed:21980503). Interacts with ESR1 and estrogen stimulates
CC       this interaction (PubMed:23160374). Interacts with the complex
CC       p35/CDK5 (PubMed:24235147). Interacts with RELA/p65 (By
CC       similarity). Interacts with KAT2B, CREBBP, EP300
CC       (PubMed:14645221). Interacts with ID1 and ID3 (By similarity).
CC       Interacts with ID2 (PubMed:20861012). Interacts with MTA1 (By
CC       similarity). Interacts with MGEA5 (By similarity). Interacts with
CC       SIRT1 (By similarity). Interacts with CIPC (By similarity).
CC       Interacts with EZH2 (By similarity). Interacts with EIF4E, PIWIL1
CC       and DDX4 (By similarity). Interacts with PER2 and CRY1 and the
CC       interaction with PER and CRY proteins requires translocation to
CC       the nucleus. Interacts with Interacts with PER1 and CRY2 (By
CC       similarity). Interaction of the CLOCK-ARNTL/BMAL1 heterodimer with
CC       PER or CRY inhibits transcription activation (PubMed:21613214).
CC       Interaction of the CLOCK-ARNTL/BMAL1 with CRY1 is independent of
CC       DNA but with PER2 is off DNA (PubMed:21613214). The CLOCK-
CC       ARNTL/BMAL1 heterodimer interacts with GSK3B. Interacts with KDM5A
CC       (PubMed:21960634). Interacts with MYBBP1A (By similarity).
CC       Interacts with THRAP3 (By similarity). Interacts with MED1; this
CC       interaction requires the presence of THRAP3 (By similarity).
CC       Interacts with NCOA2 (By similarity). The CLOCK-ARNTL/BMAL1
CC       heterodimer interacts with PASD1 (PubMed:25936801).
CC       {ECO:0000250|UniProtKB:O08785, ECO:0000269|PubMed:14645221,
CC       ECO:0000269|PubMed:20861012, ECO:0000269|PubMed:21613214,
CC       ECO:0000269|PubMed:21960634, ECO:0000269|PubMed:21980503,
CC       ECO:0000269|PubMed:23160374, ECO:0000269|PubMed:23229515,
CC       ECO:0000269|PubMed:24235147, ECO:0000269|PubMed:25936801}.
CC   -!- INTERACTION:
CC       O00327-8:ARNTL; NbExp=4; IntAct=EBI-1794265, EBI-11991546;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:14645221,
CC       ECO:0000269|PubMed:23160374}. Cytoplasm
CC       {ECO:0000250|UniProtKB:O08785}. Note=Shuffling between the
CC       cytoplasm and the nucleus is under circadian regulation and is
CC       ARNTL/BMAL1-dependent. Phosphorylated form located in the nucleus
CC       while the nonphosphorylated form found only in the cytoplasm.
CC       Sequestered to the cytoplasm in the presence of ID2 (By
CC       similarity). Localizes to sites of DNA damage in a H2AX-
CC       independent manner. {ECO:0000250|UniProtKB:O08785,
CC       ECO:0000269|PubMed:21659603}.
CC   -!- TISSUE SPECIFICITY: Hair follicles (at protein level). Expressed
CC       in all tissues examined including spleen, thymus, prostate,
CC       testis, ovary, small intestine, colon, leukocytes, heart, brain,
CC       placenta, lung, liver, skeletal muscle, kidney and pancreas.
CC       Highest levels in testis and skeletal muscle. Low levels in
CC       thymus, lung and liver. Expressed in all brain regions with
CC       highest levels in cerebellum. Highly expressed in the
CC       suprachiasmatic nucleus (SCN). {ECO:0000269|PubMed:10198158,
CC       ECO:0000269|PubMed:24005054}.
CC   -!- PTM: Ubiquitinated, leading to its proteasomal degradation.
CC       {ECO:0000250|UniProtKB:O08785}.
CC   -!- PTM: O-glycosylated; contains O-GlcNAc. O-glycosylation by OGT
CC       prevents protein degradation by inhibiting ubiquitination. It also
CC       stabilizes the CLOCK-ARNTL/BMAL1 heterodimer thereby increasing
CC       CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER1/2/3
CC       and CRY1/2. {ECO:0000250|UniProtKB:O08785}.
CC   -!- PTM: Phosphorylation is dependent on the CLOCK-ARNTL/BMAL1
CC       heterodimer formation. Phosphorylation enhances the
CC       transcriptional activity, alters the subcellular localization and
CC       decreases the stability of the heterodimer by promoting its
CC       degradation. Phosphorylation shows circadian variations in the
CC       liver. May be phosphorylated by CSNK1D and CKSN1E.
CC       {ECO:0000269|PubMed:24235147}.
CC   -!- PTM: Sumoylation enhances its transcriptional activity and
CC       interaction with ESR1, resulting in up-regulation of ESR1
CC       activity. Estrogen stimulates sumoylation. Desumoylation by SENP1
CC       negatively regulates its transcriptional activity. Sumoylation
CC       stimulates cell proliferation and increases the proportion of S
CC       phase cells in breast cancer cell lines.
CC       {ECO:0000269|PubMed:23160374}.
CC   -!- MISCELLANEOUS: CLOCK-ARNTL/BMAL1 double mutations within the PAS
CC       domains result in synergistic desensitization to high levels of
CC       CRY on repression of CLOCK-ARNTL/BMAl1 transcriptional activity of
CC       PER1 and disrupt circadian rhythmicity.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA20792.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF011568; AAB83969.1; -; mRNA.
DR   EMBL; AH008440; AAF13733.1; -; Genomic_DNA.
DR   EMBL; EF015897; ABM64208.1; -; Genomic_DNA.
DR   EMBL; AB002332; BAA20792.2; ALT_INIT; mRNA.
DR   EMBL; AK291708; BAF84397.1; -; mRNA.
DR   EMBL; BC126157; AAI26158.1; -; mRNA.
DR   EMBL; BC126159; AAI26160.1; -; mRNA.
DR   EMBL; AB005535; BAA21774.1; -; mRNA.
DR   CCDS; CCDS3500.1; -.
DR   RefSeq; NP_001254772.1; NM_001267843.1.
DR   RefSeq; NP_004889.1; NM_004898.3.
DR   RefSeq; XP_005265844.1; XM_005265787.2.
DR   RefSeq; XP_011532711.1; XM_011534409.2.
DR   RefSeq; XP_011532712.1; XM_011534410.2.
DR   RefSeq; XP_011532713.1; XM_011534411.2.
DR   RefSeq; XP_016864343.1; XM_017008854.1.
DR   UniGene; Hs.436975; -.
DR   UniGene; Hs.689578; -.
DR   PDB; 4H10; X-ray; 2.40 A; B=29-89.
DR   PDBsum; 4H10; -.
DR   ProteinModelPortal; O15516; -.
DR   SMR; O15516; -.
DR   BioGrid; 114944; 34.
DR   DIP; DIP-46009N; -.
DR   IntAct; O15516; 4.
DR   STRING; 9606.ENSP00000308741; -.
DR   iPTMnet; O15516; -.
DR   PhosphoSitePlus; O15516; -.
DR   BioMuta; CLOCK; -.
DR   EPD; O15516; -.
DR   MaxQB; O15516; -.
DR   PaxDb; O15516; -.
DR   PeptideAtlas; O15516; -.
DR   PRIDE; O15516; -.
DR   DNASU; 9575; -.
DR   Ensembl; ENST00000309964; ENSP00000308741; ENSG00000134852.
DR   Ensembl; ENST00000381322; ENSP00000370723; ENSG00000134852.
DR   Ensembl; ENST00000513440; ENSP00000426983; ENSG00000134852.
DR   GeneID; 9575; -.
DR   KEGG; hsa:9575; -.
DR   UCSC; uc003haz.3; human.
DR   CTD; 9575; -.
DR   DisGeNET; 9575; -.
DR   GeneCards; CLOCK; -.
DR   HGNC; HGNC:2082; CLOCK.
DR   HPA; HPA001867; -.
DR   HPA; HPA027565; -.
DR   MIM; 601851; gene.
DR   neXtProt; NX_O15516; -.
DR   OpenTargets; ENSG00000134852; -.
DR   PharmGKB; PA26609; -.
DR   eggNOG; ENOG410IQ5V; Eukaryota.
DR   eggNOG; ENOG410Y7Z8; LUCA.
DR   GeneTree; ENSGT00760000118788; -.
DR   HOGENOM; HOG000234382; -.
DR   HOVERGEN; HBG050997; -.
DR   InParanoid; O15516; -.
DR   KO; K02223; -.
DR   OMA; TPINMQG; -.
DR   OrthoDB; EOG091G11CV; -.
DR   PhylomeDB; O15516; -.
DR   TreeFam; TF324568; -.
DR   Reactome; R-HSA-1368082; RORA activates gene expression.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-3214847; HATs acetylate histones.
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   SIGNOR; O15516; -.
DR   ChiTaRS; CLOCK; human.
DR   GeneWiki; CLOCK; -.
DR   GenomeRNAi; 9575; -.
DR   PRO; PR:O15516; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000134852; -.
DR   CleanEx; HS_CLOCK; -.
DR   ExpressionAtlas; O15516; baseline and differential.
DR   Genevisible; O15516; HS.
DR   GO; GO:0033391; C:chromatoid body; ISS:UniProtKB.
DR   GO; GO:0005694; C:chromosome; IDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005667; C:transcription factor complex; IPI:MGI.
DR   GO; GO:0031490; F:chromatin DNA binding; ISS:UniProtKB.
DR   GO; GO:0001047; F:core promoter binding; ISS:UniProtKB.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0070888; F:E-box binding; IDA:UniProtKB.
DR   GO; GO:0004402; F:histone acetyltransferase activity; IMP:UniProtKB.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
DR   GO; GO:0000978; F:RNA polymerase II core promoter proximal region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0043565; F:sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0000982; F:transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding; ISS:BHF-UCL.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0001190; F:transcriptional activator activity, RNA polymerase II transcription factor binding; ISS:BHF-UCL.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IDA:UniProtKB.
DR   GO; GO:0032922; P:circadian regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; TAS:Reactome.
DR   GO; GO:0000077; P:DNA damage checkpoint; IMP:UniProtKB.
DR   GO; GO:2000323; P:negative regulation of glucocorticoid receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0009648; P:photoperiodism; TAS:ProtInc.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IGI:MGI.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; ISS:UniProtKB.
DR   GO; GO:0042634; P:regulation of hair cycle; IMP:UniProtKB.
DR   GO; GO:0050796; P:regulation of insulin secretion; ISS:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; TAS:ProtInc.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:2000074; P:regulation of type B pancreatic cell development; ISS:UniProtKB.
DR   GO; GO:0051775; P:response to redox state; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007283; P:spermatogenesis; ISS:UniProtKB.
DR   CDD; cd00083; HLH; 1.
DR   CDD; cd00130; PAS; 2.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR001067; Nuc_translocat.
DR   InterPro; IPR001610; PAC.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR013767; PAS_fold.
DR   Pfam; PF00010; HLH; 1.
DR   Pfam; PF00989; PAS; 1.
DR   PRINTS; PR00785; NCTRNSLOCATR.
DR   SMART; SM00353; HLH; 1.
DR   SMART; SM00086; PAC; 1.
DR   SMART; SM00091; PAS; 2.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   SUPFAM; SSF55785; SSF55785; 2.
DR   PROSITE; PS50888; BHLH; 1.
DR   PROSITE; PS50112; PAS; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Acyltransferase; Biological rhythms;
KW   Complete proteome; Cytoplasm; DNA damage; DNA-binding;
KW   Isopeptide bond; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Transcription; Transcription regulation;
KW   Transferase; Ubl conjugation.
FT   CHAIN         1    846       Circadian locomoter output cycles protein
FT                                kaput.
FT                                /FTId=PRO_0000127163.
FT   DOMAIN       34     84       bHLH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00981}.
FT   DOMAIN      107    177       PAS 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00140}.
FT   DOMAIN      262    332       PAS 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00140}.
FT   DOMAIN      336    379       PAC.
FT   REGION      371    845       Interaction with NR3C1.
FT                                {ECO:0000250|UniProtKB:O08785}.
FT   REGION      450    570       Interaction with SIRT1.
FT                                {ECO:0000250|UniProtKB:O08785}.
FT   REGION      514    564       Implicated in the circadian rhythmicity.
FT                                {ECO:0000250}.
FT   MOTIF        32     47       Nuclear localization signal.
FT                                {ECO:0000250|UniProtKB:O08785}.
FT   COMPBIAS    744    760       Gln-rich.
FT   COMPBIAS    819    828       Poly-Gln.
FT   SITE         39     39       Interaction with E-box DNA.
FT                                {ECO:0000269|PubMed:23229515}.
FT   SITE         43     43       Interaction with E-box DNA.
FT                                {ECO:0000269|PubMed:23229515}.
FT   SITE         47     47       Interaction with E-box DNA.
FT                                {ECO:0000269|PubMed:23229515}.
FT   SITE         84     84       Important for interaction with
FT                                ARNTL/BMAL1.
FT                                {ECO:0000269|PubMed:23229515}.
FT   MOD_RES      38     38       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O08785}.
FT   MOD_RES      42     42       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O08785}.
FT   MOD_RES     408    408       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O08785}.
FT   MOD_RES     427    427       Phosphoserine; by GSK3-beta.
FT                                {ECO:0000250|UniProtKB:O08785}.
FT   MOD_RES     431    431       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O08785}.
FT   MOD_RES     451    451       Phosphothreonine; by CDK5.
FT                                {ECO:0000269|PubMed:24235147}.
FT   MOD_RES     461    461       Phosphothreonine; by CDK5.
FT                                {ECO:0000269|PubMed:24235147}.
FT   CROSSLNK     67     67       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000250|UniProtKB:O08785}.
FT   CROSSLNK    842    842       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000250|UniProtKB:O08785}.
FT   VARIANT     208    208       S -> C (in dbSNP:rs34897046).
FT                                /FTId=VAR_040061.
FT   VARIANT     380    380       E -> K (in dbSNP:rs1056478).
FT                                /FTId=VAR_040062.
FT   VARIANT     395    395       L -> I (in dbSNP:rs6855837).
FT                                /FTId=VAR_029076.
FT   VARIANT     542    542       H -> R (in dbSNP:rs3762836).
FT                                /FTId=VAR_029077.
FT   MUTAGEN      38     38       S->E: Phosphomimetic mutant with no
FT                                effect on DNA binding or CLOCK-
FT                                ARNTL/BMAL1 transcriptional activity.
FT                                {ECO:0000269|PubMed:23229515}.
FT   MUTAGEN      42     42       S->E: Phosphomimetic mutant with no
FT                                effect on DNA binding or CLOCK-
FT                                ARNTL/BMAL1 transcriptional activity.
FT                                {ECO:0000269|PubMed:23229515}.
FT   MUTAGEN      50     50       F->M: No effect on ARNTL/BMAL1 binding.
FT                                {ECO:0000269|PubMed:23229515}.
FT   MUTAGEN      84     84       H->L: Impaired ARNTL/BMAL1 binding.
FT                                {ECO:0000269|PubMed:23229515}.
FT   MUTAGEN     116    116       E->K: 3-fold increase in PER1 reporter
FT                                activity by CLOCK-ARNTL/BMAL1. Some
FT                                reduction of CRY1 inhibition of CLOCK-
FT                                ARNTL/BMAL1 transcriptional activity;
FT                                when associated with K-367 and L-601.
FT                                {ECO:0000269|PubMed:16474406}.
FT   MUTAGEN     332    332       G->E: 3-fold increase in PER1 reporter
FT                                activity by CLOCK-ARNTL/BMAL1. Some
FT                                reduction of CRY1 inhibition of CLOCK-
FT                                ARNTL/BMAL1 transcriptional activity;
FT                                when associated with L-840.
FT                                {ECO:0000269|PubMed:16474406}.
FT   MUTAGEN     360    360       H->Y: 3-fold increase in PER1 reporter
FT                                activity by CLOCK-ARNTL/BMAL1. Some
FT                                reduction of CRY1 inhibition of CLOCK-
FT                                ARNTL/BMAL1 transcriptional activity.
FT                                {ECO:0000269|PubMed:16474406}.
FT   MUTAGEN     367    367       E->K: 3-fold increase in PER1 reporter
FT                                activity by CLOCK-ARNTL/BMAL1. Some
FT                                reduction of CRY1 inhibition CLOCK-
FT                                ARNTL/BMAL1 transcriptional activity;
FT                                when associated with E-116 and L-601.
FT                                {ECO:0000269|PubMed:16474406}.
FT   MUTAGEN     451    451       T->F: Significant loss in
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:24235147}.
FT   MUTAGEN     461    461       T->F: Significant loss in
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:24235147}.
FT   MUTAGEN     601    601       V->L: 3-fold increase in PER1 reporter
FT                                activity by CLOCK-ARNTL/BMAL1. Some
FT                                reduction of CRY1 inhibition of CLOCK-
FT                                ARNTL/BMAL1 transcriptional activity;
FT                                when associated with K-116 and K-367.
FT                                {ECO:0000269|PubMed:16474406}.
FT   MUTAGEN     840    840       P->L: 3-fold increase in PER1 reporter
FT                                activity by CLOCK-ARNTL/BMAL1. Some
FT                                reduction of CRY1 inhibition of CLOCK-
FT                                ARNTL/BMAL1 transcriptional activity;
FT                                when associated with E-332.
FT                                {ECO:0000269|PubMed:16474406}.
FT   CONFLICT    440    440       S -> P (in Ref. 1; AAF13733).
FT                                {ECO:0000305}.
FT   HELIX        33     58       {ECO:0000244|PDB:4H10}.
FT   STRAND       61     63       {ECO:0000244|PDB:4H10}.
FT   HELIX        70     89       {ECO:0000244|PDB:4H10}.
SQ   SEQUENCE   846 AA;  95304 MW;  C292B451A33E4CBF CRC64;
     MLFTVSCSKM SSIVDRDDSS IFDGLVEEDD KDKAKRVSRN KSEKKRRDQF NVLIKELGSM
     LPGNARKMDK STVLQKSIDF LRKHKEITAQ SDASEIRQDW KPTFLSNEEF TQLMLEALDG
     FFLAIMTDGS IIYVSESVTS LLEHLPSDLV DQSIFNFIPE GEHSEVYKIL STHLLESDSL
     TPEYLKSKNQ LEFCCHMLRG TIDPKEPSTY EYVKFIGNFK SLNSVSSSAH NGFEGTIQRT
     HRPSYEDRVC FVATVRLATP QFIKEMCTVE EPNEEFTSRH SLEWKFLFLD HRAPPIIGYL
     PFEVLGTSGY DYYHVDDLEN LAKCHEHLMQ YGKGKSCYYR FLTKGQQWIW LQTHYYITYH
     QWNSRPEFIV CTHTVVSYAE VRAERRRELG IEESLPETAA DKSQDSGSDN RINTVSLKEA
     LERFDHSPTP SASSRSSRKS SHTAVSDPSS TPTKIPTDTS TPPRQHLPAH EKMVQRRSSF
     SSQSINSQSV GSSLTQPVMS QATNLPIPQG MSQFQFSAQL GAMQHLKDQL EQRTRMIEAN
     IHRQQEELRK IQEQLQMVHG QGLQMFLQQS NPGLNFGSVQ LSSGNSSNIQ QLAPINMQGQ
     VVPTNQIQSG MNTGHIGTTQ HMIQQQTLQS TSTQSQQNVL SGHSQQTSLP SQTQSTLTAP
     LYNTMVISQP AAGSMVQIPS SMPQNSTQSA AVTTFTQDRQ IRFSQGQQLV TKLVTAPVAC
     GAVMVPSTML MGQVVTAYPT FATQQQQSQT LSVTQQQQQQ SSQEQQLTSV QQPSQAQLTQ
     PPQQFLQTSR LLHGNPSTQL ILSAAFPLQQ STFPQSHHQQ HQSQQQQQLS RHRTDSLPDP
     SKVQPQ
//
